Docusign (NASDAQ:DOCU) CEO Allan Thygesen Sells 40,000 Shares

Docusign Inc. (NASDAQ:DOCU) CEO Allan Thygesen sold 40,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $69.69, for a total transaction of $2,787,600.00. Following the transaction, the chief executive officer owned 136,246 shares in the company, valued at $9,494,983.74. The trade was a 22.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Docusign Price Performance

Shares of NASDAQ DOCU opened at $68.10 on Friday. Docusign Inc. has a 12-month low of $61.91 and a 12-month high of $107.86. The company has a market capitalization of $13.69 billion, a PE ratio of 51.20, a price-to-earnings-growth ratio of 3.43 and a beta of 1.02. The firm’s 50-day moving average is $76.37 and its two-hundred day moving average is $79.20.

Docusign (NASDAQ:DOCU) last announced its quarterly earnings results on Thursday, September 4th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.08. Docusign had a net margin of 9.08% and a return on equity of 14.01%. The company had revenue of $800.64 million for the quarter, compared to the consensus estimate of $780.35 million. During the same quarter in the prior year, the firm earned $0.97 earnings per share. The company’s revenue for the quarter was up 8.8% compared to the same quarter last year. Docusign has set its Q3 2026 guidance at EPS. FY 2026 guidance at EPS. On average, analysts forecast that Docusign Inc. will post 1.17 EPS for the current fiscal year.

Docusign announced that its Board of Directors has initiated a stock repurchase plan on Thursday, June 5th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 6.6% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On Docusign

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LLC increased its position in Docusign by 23.6% during the second quarter. Corient Private Wealth LLC now owns 27,937 shares of the company’s stock worth $2,176,000 after purchasing an additional 5,333 shares during the last quarter. WT Wealth Management acquired a new position in Docusign during the second quarter worth approximately $1,615,000. Centaurus Financial Inc. increased its position in Docusign by 2.6% during the second quarter. Centaurus Financial Inc. now owns 5,398 shares of the company’s stock worth $420,000 after purchasing an additional 136 shares during the last quarter. Orion Porfolio Solutions LLC increased its position in Docusign by 50.8% during the second quarter. Orion Porfolio Solutions LLC now owns 23,832 shares of the company’s stock worth $1,856,000 after purchasing an additional 8,031 shares during the last quarter. Finally, Neuberger Berman Group LLC increased its position in Docusign by 17.2% during the second quarter. Neuberger Berman Group LLC now owns 51,294 shares of the company’s stock worth $3,995,000 after purchasing an additional 7,511 shares during the last quarter. Institutional investors and hedge funds own 77.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. UBS Group set a $95.00 price target on shares of Docusign in a report on Friday, September 5th. Zacks Research raised shares of Docusign from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 9th. Royal Bank Of Canada upped their price objective on shares of Docusign from $90.00 to $95.00 and gave the company a “sector perform” rating in a research note on Friday, September 5th. Bank of America upped their price objective on shares of Docusign from $85.00 to $102.00 and gave the company a “neutral” rating in a research note on Friday, September 5th. Finally, Morgan Stanley upped their price objective on shares of Docusign from $86.00 to $90.00 and gave the company an “equal weight” rating in a research note on Monday, September 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and fourteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $94.14.

Docusign Company Profile

DocuSign, Inc provides electronic signature solution in the United States and internationally. The company provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; Document Generation streamlines the process of generating new, custom agreements; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce.